How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

345 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

who are currently receiving another investigational drug. Anti-cancer agents: Patients who are currently receiving other anti-cancer agents. The following CYP3A4 inducers are prohibited 12 days before the start of Sutent® and during the study with Sutent®: rifampin, rifabutin, carbamazepine, Phenobarbital, phenytoin, St. John's wort, efavirenz, and tipranavir. Anti-thrombotic and anti-platelet agents: warfarin (Coumadin), heparin, low molecular weight heparin, aspirin, and/or ibuprofen, or other

2011 Clinical Trials

182. A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

study. azole antifungals (ketoconazole, itraconazole, miconazole, fluconazole) HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir) clarithromycin verapamil erythromycin delavirdine diltiazem nefazodone telithromycin Inducers- prohibited 12 days before dosing and during study. rifampin phenytoin rifabutin St. John's wort carbamazepine efavirenz phenobarbital tipranavir Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2011 Clinical Trials

183. Oral Versus Intravenous Dexamethasone

. phenytoin, barbiturates, rifampicin, erythromycin, clarithromycin, aprepitant, colchicine, everolimus, itraconazole, ketoconazole, pazopanib, tipranavir, and vinorelbine) Moribund patients (defined as expected to die within 24 hours) Patients with proven or suspected allergy to dexamethasone Patients not capable of taking tablets orally Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2011 Clinical Trials

184. Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients

(dihydroergotamine, ergotamine), monoamine oxidase inhibitors (phenelzine, isocarboxazid, selegiline, or moclobemide), pimozide, or terfenadine. Pregnancy or breast-feeding. Hypokalemia Concomitant use of other P-gp inhibitors/inducers, e.g. amiodarone, verapamil, digoxin, tipranavir/ritonavir, lovastatin, tariquidar, itraconazole, dipyridamol, erythromycin, ritonavir, quinidine. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2011 Clinical Trials

185. -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

, nelfinavir, ritonavir, saquinavir, diltiazem, verapamil and grapefruit juice. Use of drugs that are known potent CYP3A4 inducers within 12 days prior to the first dose of study medication, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifabutin, rifampin, tipranavir, ritonavir, and St. John s wort. Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but not limited to pimozide, aripiprazole, triazolam, ergotamine

2011 Clinical Trials

186. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience. (PubMed)

. The incremental annual cost per additional patient achieving undetectable plasma HIV-RNA levels with DRV/r versus control PI-based HAART in POWER 1 and 2 (£4148) compared favourably with that determined for enfuvirtide (£137, 740; TORO trials) and tipranavir/ritonavir (£32,176; RESIST) versus control therapy.DRV/r-based HAART provided consistent reductions in the cost of achieving undetectable plasma HIV-RNA levels compared with control PI-based therapy in highly treatment-experienced patients across various

2010 PharmacoEconomics

187. HIV-1 Protease Mutations and Protease Inhibitor Cross Resistance. (PubMed)

to atazanavir; 1,265 isolates had been tested for susceptibility to tipranavir; and 642 isolates had been tested for susceptibility to darunavir. We applied least-angle regression (LARS) to the 200 most common mutations in the data set and identified a set of 46 mutations associated with decreased PI susceptibility of which 40 were not polymorphic in the eight most common HIV-1 group M subtypes. We then used least-squares regression to ascertain the relative contribution of each of these 46 mutations

Full Text available with Trip Pro

2010 Antimicrobial Agents and Chemotherapy

188. Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a(R)-bis-Tetrahydrofuranylurethane (bis-THF) That Are Potent Against Multi-PI-Resistant HIV-1 Variants In Vitro. (PubMed)

, M46L, V82I, and I84V mutations remained relatively sensitive to PIs, including darunavir, with the EC50s being 3- to 8-fold-greater than the EC50 of each drug for HIV-1NL4-3. Interestingly, HIV216-0.16 microM had 10-fold increased sensitivity to tipranavir. Analysis of the protein-ligand X-ray structures of GRL-216 revealed that the macrocycle occupied a greater volume of the binding cavity of protease and formed greater van der Waals interactions with V82 and I84 than darunavir. The present data

Full Text available with Trip Pro

2010 Antimicrobial Agents and Chemotherapy

189. Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Tipranavir Full dose anticoagulation with warfarin (coumadin) or other vitamin K dependent anticoagulant. Low-dose prophylactic warfarin (i.e. 1mg per day port prophylaxis) is allowable. Low molecular heparin (e.g., danaparoid, dalteparin, tinzaparin, enoxaparin) is allowable if patient has been established on therapy. Have received an estimated dose of radiation therapy to >35% of the bone marrow. Patients previously exposed to mTOR inhibitors are permitted in phase 1A but not allowed in phase 1B

2010 Clinical Trials

190. IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

will be stratified by medication, HIV status and HIV antiretroviral therapy as follows: Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir. *PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir Amphetamine (...) / dextroamphetamine Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows: Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir. *PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir

2010 Clinical Trials

191. Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will help the Thai government in planning its strategy to provide third line ARV therapy to children within the national program. Condition or disease Intervention/treatment This Study (...) may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 56 participants Observational Model: Cohort Time Perspective: Other Official Title: Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy Study Start Date : August 2010 Actual

2010 Clinical Trials

192. Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours

to interact with pantoprazole, including: The anti-fungal agents fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole; The antiviral agents: atazanavir, delavirdine, indinavir, nelfinavir, raltegravir, saquinavir, tipranavir; The anticoagulant agents: clopidogrel, dabigatran; The immunosuppressive agent: mycophenolate The anti-inflammatory agent: mesalamine Patients who are receiving oral pantoprazole or other PPI inhibitors may participate if these agents are discontinued at least 7 days

2010 Clinical Trials

193. Study on Interleukin-7 (CYT107) in HIV Patients

not be enrolled. HIV-2, HTLV-1 or HTLV-2 seropositivity. Pregnant or lactating women. Women of childbearing potential must have a negative serum or urine pregnancy test within 1 week prior to study entry. Refusal or inability to practice contraception regardless of the gender of the patient. Hypertension with a resting systolic blood pressure > 140 or a resting diastolic blood pressure > 90 mm despite adequate antihypertensive treatment. Use of tipranavir/ritonavir (TPV/r) and Enfuvirtide (T-20). Contacts

2010 Clinical Trials

194. Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

(single-arm study) The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen. Drug: Maraviroc FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks. Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks. Subjects

2010 Clinical Trials

195. GORD in children

of saquinavir. Tipranavir — concurrent use with omeprazole is contraindicated. [ ] Supporting evidence Supporting evidence The supporting evidence for the recommendations in this CKS topic is summarized in the National Institute for Health and Care Excellence (NICE) guideline, Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people [ ]. NICE summarized the evidence on treatments for GORD in children. For a more detailed discussion of the basis for the NICE

2009 NICE Clinical Knowledge Summaries

196. Both a Protective and a Deleterious Role for the L76V Mutation (PubMed)

Pyridines 0 Pyrimidinones 0 Pyrones 0 Sulfonamides 2494G1JF75 Lopinavir EC 3.4.23.- HIV Protease EC 3.4.23.- p16 protease, Human immunodeficiency virus 1 YO603Y8113 Darunavir ZZT404XD09 tipranavir IM Acquired Immunodeficiency Syndrome drug therapy virology Anti-HIV Agents therapeutic use Darunavir Drug Resistance, Multiple, Viral genetics HIV Protease genetics HIV Protease Inhibitors therapeutic use HIV-1 Humans Lopinavir Mutation Pyridines therapeutic use Pyrimidinones therapeutic use Pyrones

Full Text available with Trip Pro

2009 Antimicrobial Agents and Chemotherapy

197. Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

, including any of the following: Ketoconazole Itraconazole Clarithromycin Erythromycin Diltiazem Verapamil Delavirdine Indinavir Saquinavir Ritonavir Atazanavir Nelfinavir At least 12 days since prior and no concurrent potent CYP3A inducers, including any of the following: Rifampin Rifabutin Carbamazepine Phenobarbital Phenytoin St. John's wort Efavirenz Tipranavir Concurrent radiotherapy allowed provided sunitinib malate is stopped one day before and resumed one day after radiotherapy Concurrent

2009 Clinical Trials

198. Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF, darunavir/cobicistat Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 176 participants Observational Model: Case-Crossover Time Perspective: Prospective Official Title: Study on Pharmacokinetics (...) (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population HIV-infected pregnant women using at least one of the following antiretroverial agents: Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; Raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc

2009 Clinical Trials

199. A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Study Description Go to Brief Summary: The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor. Condition or disease Intervention/treatment HIV Infections Drug: Tipranavir Drug: ritonavir Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 42 participants Observational Model (...) : Cohort Time Perspective: Prospective Official Title: A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice. Study Start Date : September 2009 Actual Primary Completion Date : July 2011 Actual Study Completion Date : July 2011 Resource links provided by the National Library of Medicine related topics: available for: Groups

2009 Clinical Trials

200. Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

approach. Condition or disease Intervention/treatment Phase HIV HIV Infections Drug: maraviroc Drug: control group Phase 4 Detailed Description: This is a 48 week randomized, prospective, controlled, open-label, proof-of-concept pilot clinical trial. Patients with HIV-1 infection on HAART regimen including 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or ATV/unboosted (...) the NNRTI/PI to maraviroc to switch from the NNRTI/PI to maraviroc Drug: maraviroc HAART regimen including 2 NRTI/NtRTIs plus maraviroc Active Comparator: to continue with the same approach to continue with the same approach Drug: control group HAART regimen including 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or ATV/unboosted (in a regimen without tenofovir) or 1 NNRTI

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>